Want to see LEGN full AI Analyst Report?
LEGN Stock Chart & Stats
$21.17
-$0.50(-1.49%)
At close: 4:00 PM EST
$21.17
-$0.50(-1.49%)
Day’s Range― - ―
52-Week Range$16.24 - $45.30
Previous CloseN/A
Volume249.07K
Average Volume (3M)2.48M
Market Cap
$4.22B
Enterprise Value$2.90K
Total Cash (Recent Filing)$834.63M
Total Debt (Recent Filing)$389.31M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 18, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding193,439,790
10 Day Avg. Volume1,780,322
30 Day Avg. Volume2,483,178
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)4.00
Price to Sales (P/S)3.89
P/FCF Ratio-23.85
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$54.85Price Target Upside159.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.02
Revenue Forecast (FY)$1.43B
Bulls Say, Bears Say
Bulls Say
Revenue Scale & Gross ProfitabilityRapid, durable revenue scale driven by CARVYKTI provides a stable commercial base to fund operations and R&D. Sustained ~54% gross margins give structural capacity to absorb commercialization and manufacturing costs, support reinvestment, and improve operating leverage as sales broaden globally.
Manufacturing And Supply ReliabilityHighly reliable manufacturing reduces supply bottlenecks that historically constrain CAR‑T adoption. Consistent turnarounds and on‑time deliveries enable broader community site use and earlier‑line penetration, lowering per‑patient cost risk and supporting durable commercial expansion and margin stability over multiple quarters.
Strong Cash Position And Limited LeverageA sizable cash balance with no long‑term debt provides structural financial flexibility to fund manufacturing scale, IND filings and early clinical programs without immediate refinancing. This reduces near‑term liquidity risk, allowing management to execute multi‑quarter commercial and R&D plans with less pressure to cut growth investments.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the company remains reliant on external financing or collaboration inflows to sustain growth and R&D. Over a multi‑quarter horizon this raises dilution or funding‑cost risk if commercial scaling or milestone receipts slow, constraining long‑term capital allocation flexibility.
Ongoing GAAP Losses And Negative ROEMaterial GAAP losses and steep negative ROE indicate shareholder capital is not yet generating returns. Even with adjusted profitability guidance, persistent accounting losses and margin volatility can limit the company's ability to demonstrate sustainable economics and may prolong dependence on partners and milestone payments.
Clinical Timing And Competitive RiskKey label‑expansion readouts are event‑driven with uncertain timing, delaying potential revenue inflections and milestone triggers. Early In Vivo data are promising but small and preliminary. Coupled with rising competition (e.g., bispecifics) and partner program shifts, this creates durable execution and market‑share risk over the next several quarters.
Legend Biotech News
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $16.24 and its highest was $45.30 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Legend Biotech Corporation’s market cap is $4.22B.
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Aug 18, 2026 which is in 31 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on May 12, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of $0.012 by -$0.162.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is 0.05.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 193,439,790 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.15 in its last earnings report, missing expectations of $0.012. Following the earnings report the stock price went up 10.477%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Currently, no hedge funds are holding shares in LEGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Legend Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.85 (159.09% Upside)
$54.85 (159.09% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $171.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-42.86%
12-Months-Change
Fundamentals
Return on Equity
-24.91%
Trailing 12-Months
Asset Growth
-1.17%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
LEGN Stock 12 Month Forecast
Average Price Target
$54.85
▲(159.09% Upside)
Technical Analysis
Cytokinetics
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Atrium Therapeutics, Inc.
―
Abivax SA Sponsored ADR
―
Ownership Overview
0.15% Insiders
13.26% Mutual Funds
1.02% Other Institutional Investors
82.54% Public Companies and
Individual Investors